Optimal Management of Early-Stage HCC

Insights From: Richard Finn, MD, David Geffen School of Medicine at UCLA



Key Takeaways:

The importance of multidisciplinary management of the underlying liver disease and function as well as the tumor burden in patients with hepatocellular carcinoma (HCC).

Solidifying interactions among locoregional practitioners, interventional radiologists, medical oncologists, and hepatologists to help define when to cease TACE (transarterial chemoembolization) and start a patient on systemic therapy.

Triggers to discontinue locoregional therapy and move to systemic therapy.
Printer Printing...